M&A Deal Summary

ZIOPHARAM Oncology Acquires Baxter International - Indibulin

On November 6, 2006, ZIOPHARAM Oncology acquired life science company Baxter International - Indibulin from Baxter International

Acquisition Highlights
  • This is ZIOPHARAM Oncology’s 1st transaction in the Life Science sector.
  • This is ZIOPHARAM Oncology’s 1st transaction in the United States.
  • This is ZIOPHARAM Oncology’s 1st transaction in Illinois.

M&A Deal Summary
Date 2006-11-06
Target Baxter International - Indibulin
Sector Life Science
Buyer(s) ZIOPHARAM Oncology
Sellers(s) Baxter International
Deal Type Divestiture

Target

Baxter International - Indibulin

Deerfield, Illinois, United States
Baxter International, Inc. - Indibulin is a novel synthetic anti-cancer agent that targets mitosis like the taxanes.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ZIOPHARAM Oncology

Boston, Massachusetts, United States
Category Company
Sector Life Science
Employees103
Revenue 6M USD (2017)
DESCRIPTION

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safer, more effective and scalable cell-based therapies for the treatment of cancer. ZIOPHARAM Oncology is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Illinois) 1 of 1
Country (United States) 1 of 1
Year (2006) 1 of 1

Seller(S) 1

SELLER

Baxter International

Deerfield, Illinois, United States
Category Company
Founded 1931
Sector Medical Products
Employees60,000
Revenue 14.8B USD (2023)
DESCRIPTION
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.

Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.

DEAL STATS #
Overall 3 of 7
Sector (Life Science) 1 of 4
Type (Divestiture) 3 of 6
State (Illinois) 1 of 4
Country (United States) 2 of 5
Year (2006) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-09-02 COMPASS Services

United States

COMPASS Services is a leading provider of intravenous admixture services supplied to the hospital and alternate site pharmacies market.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-09-01 Edwards Lifesciences - Hemofiltration Product Line

Irvine, California, United States

Edwards Lifesciences Corp. - Hemofiltration Product Line includes manufacturer of medical products in US.

Buy -
Mergr

Product

Company

Legal